Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.42 |
| ▸ | LAP3 | P28838 | 4/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL21253128 | 0.97 | ANPEP (0.41) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL250204 | 0.78 | FDPS (0.50) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL2786515 | 0.78 | ANPEP (0.61) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL5496445 | 0.76 | ANPEP (0.52) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL2597927 | 0.76 | FDPS (0.50) | ANPEPLAP3ERAP2FDPSALDH1A1 | |
| SCHEMBL8713308 | 0.76 | FDPS (0.48) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL8709594 | 0.76 | FDPS (0.48) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL29449121 | 0.76 | FDPS (0.48) | ANPEPLAP3ERAP1ERAP2FDPS | |
| SCHEMBL2639189 | 0.74 | FDPS (0.48) | ANPEPLAP3ERAP2FDPSALDH1A1 | |
| SCHEMBL5496452 | 0.74 | ANPEP (0.39) | ANPEPLAP3ERAP1ERAP2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371232-B1 | TWO-PARTS ADHESIVE SYSTEM | LORD CORP (US) | 2021-01-06 | — | — | EP | claimed |
| EP-1392325-B1 | METHOD OF ADMINISTRATION OF BISPHOSPHONATES BY INHALATION IN THE TREATMENT OR PREVENTION OF BONE RESORPTION AND OSTEOPOROSIS | NOVARTIS AG (CH) | 2006-06-21 | — | — | EP | claimed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | claimed |
| US-20040127466-A1 | Inhalation administration of bisphosphonates | PALEPU NAGESWARA R (US) | 2004-07-01 | — | — | US | claimed |
| EP-1392325-A1 | METHOD OF ADMINISTRATION OF BISPHOSPHONATES BY INHALATION IN THE TREATMENT OR PREVENTION OF BONE RESORPTION AND OSTEOPOROSIS | Novartis AG (CH) | 2004-03-03 | — | — | EP | claimed |
| EP-1339411-A2 | USE OF BISPHOSPHONATES FOR PAIN TREATMENT | Novartis AG (CH) | 2003-09-03 | — | — | EP | claimed |
| US-20030064966-A1 | Inhalation administration of biophosphonates | GENEVA PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | claimed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| WO-2002089816-A1 | METHOD OF ADMINISTRATION OF BISPHOSPHONATES BY INHALATION IN THE TREATMENT OR PREVENTION OF BONE RESORPTION AND OSTEOPOROSIS | NOVARTIS AG (CH) | 2002-11-14 | — | — | WO | claimed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | claimed |
| EP-0779812-A4 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE | PROCTER & GAMBLE (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0779812-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-25 | — | — | EP | claimed |
| EP-0758241-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | Novartis AG (CH) | 1997-02-19 | — | — | EP | claimed |
| WO-1996007417-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE | THE PROCTER & GAMBLE COMPANY (US) | 1996-03-14 | — | — | WO | claimed |
| EP-0690719-A4 | — | — | 1996-01-24 | — | — | EP | claimed |
| EP-0690719-A1 | DRY MIX FORMULATION FOR BISPHOSPHONIC ACIDS | MERCK & CO. INC. (US) | 1996-01-10 | — | — | EP | claimed |
| WO-1995030421-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | claimed |
| WO-1994012200-A1 | DRY MIX FORMULATION FOR BISPHOSPHONIC ACIDS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | claimed |
| EP-0563096-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1993-10-06 | — | — | EP | claimed |
| EP-0201057-A2 | Bone targeted inhibitors of carbonic anhydrase | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1986-11-12 | — | — | EP | claimed |